Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

The user experienced significant hair regrowth and thickening using Minoxidil, Finasteride, and Regenepure DR. They reported no major side effects except for an itchy scalp.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

User started hair loss treatment 3 months ago using topical fin, minoxidil, RU58841, stemoxydine, and microneedling. Others noticed improvement in mid and frontal scalp areas and suggested considering oral minoxidil.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

The user is using finasteride 1.25mg three times a week for hair regrowth and reports no significant side effects except watery semen initially. They also use a local caffeine shampoo and are considering haircuts to improve appearance.

A user's scalp issue that may be causing their hair loss and potential treatments, such as salicylic acid, finasteride, minoxidil, ketoconazole shampoo, and visiting a dermatologist.

User shares 3-month progress with Big3 treatment (finasteride 0.15mg, minox twice a day, 0.75mm microneedling weekly). Others discuss results, dosage, and potential benefits of higher finasteride dose.

The conversation is about hair loss and the conclusion is that genetics play a significant role in hair loss, and lifestyle choices or being a well-adjusted person do not prevent male pattern baldness.

Experimenting with the effects of creatine and finasteride on DHT levels, as well as a discussion regarding the potential link between creatine supplementation and hair loss.

CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The user experienced successful hair regrowth over 610 days using Finasteride, Minoxidil, and Nizoral shampoo, with no side effects and improved mood. They encourage patience in the hair growth process.

A 30-year-old male reports reduced shedding and positive progress in hair regrowth after nearly three months of using topical finasteride and minoxidil daily, along with derma rolling twice a week. He also takes supplements like pumpkin seed oil, biotin, multivitamins, and fish oil.

A 21-year-old is experiencing aggressive hair loss and dandruff, possibly due to seborrheic dermatitis, and is using pumpkin seed oil, scalp massages, and anti-dandruff shampoo as treatments. They are hesitant to use prescribed Finasteride and Minoxidil and have noticed some improvement after stopping Serenoa capsules.

User starts final hair loss regimen with various treatments and plans to leave subreddit for mental health. Others believe user's hair is fine and the regimen is unnecessary and potentially harmful.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The user is treating hair loss with a regimen including Dutasteride, oral and topical Minoxidil, microneedling, and various supplements for overall health. They are considering adding tretinoin, stemoxydine/RU, DIM, Boron, and Fadogia Agretis to their routine.

Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.

Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.

The conversation discusses Shiseido's RepliCel Hair-01 technology for hair regeneration, which aims to stop hair loss with minimal regrowth. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

Age-linked hair loss is linked to disappearing collagen. Treatments discussed include minoxidil, finasteride, RU58841, tretinoin, microneedling, and collagen supplements.

The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.

The user shared their nearly 3-year hair loss treatment journey, starting with minoxidil, then adding finasteride, nizoral shampoo, and microneedling, later incorporating oral minoxidil and RU58841, and recently switching to dutasteride. They are considering replacing RU58841 with pyrilutamide and are aware of the potential side effects of oral minoxidil on heart health.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

User reports hair loss improvement with twice-weekly 0.25mg Fin, twice-weekly Min, weekly 0.5mm microneedling, and daily massages. Unconventional regimen contradicts typical advice but may reduce side effects.